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Abstract: BACKGROUND Prolonged amenorrhoea occurs as a consequence of functional hypothalamic
amenorrhoea (FHA) which is most often induced by weight loss, vigorous exercise or emotional stress.
Unfortunately, removal of these triggers does not always result in the return of menses. The prevalence
and conditions underlying the timing of return of menses vary strongly and some women report amen-
orrhoea several years after having achieved and maintained normal weight and/or energy balance. A
better understanding of these factors would also allow improved counselling in the context of infertility.
Although BMI, percentage body fat and hormonal parameters are known to be involved in the initiation
of the menstrual cycle, their role in the physiology of return of menses is currently poorly understood. We
summarise here the current knowledge on the epidemiology and physiology of return of menses. OBJEC-
TIVE AND RATIONALE The aim of this review was to provide an overview of (i) factors determining
the recovery of menses and its timing, (ii) how such factors may exert their physiological effects and
(iii) whether there are useful therapeutic options to induce recovery. SEARCH METHODS We searched
articles published in English, French or German language containing keywords related to return of menses
after FHA published in PubMed between 1966 and February 2020. Manuscripts reporting data on either
the epidemiology or the physiology of recovery of menses were included and bibliographies were reviewed
for further relevant literature. The Strengthening the Reporting of Observational Studies in Epidemi-
ology (STROBE) criteria served to assess quality of observational studies. OUTCOMES Few studies
investigate return of menses and most of them have serious qualitative and methodological limitations.
These include (i) the lack of precise definitions for FHA or resumption of menses, (ii) the use of short
observation periods with unsatisfactory descriptions and (iii) the inclusion of poorly characterised small
study groups. The comparison of studies is further hampered by very inhomogeneous study designs.
Consequently, the exact prevalence of resumption of menses after FHA is unknown. Also, the timepoint
of return of menses varies strongly and reliable prediction models are lacking. While weight, body fat
and energy availability are associated with the return of menses, psychological factors also have a strong
impact on the menstrual cycle and on behaviour known to increase the risk of FHA. Drug therapies
with metreleptin or naltrexone might represent further opportunities to increase the chances of return of
menses, but these require further evaluation.
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Pape, J; Herbison, A E; Leeners, B (2021). Recovery of menses after functional hypothalamic amenor-





Recovery of menses after functional hypothalamic amenorrhea 1 
– if, when and why  2 
J. Pape 1, A.E. Herbison 2, B. Leeners 1,3 3 
 4 
1) Department of Reproductive Endocrinology, University Hospital Zurich, 8091 Zurich, Switzerland 5 
2) Department of Physiology, Development and Neuroscience, University of Cambridge, CB2 3EG United 6 
Kingdom 7 
3) University of Zurich, 8091 Zurich, Switzerland 8 
 9 
 10 
Running title: Recovery of menses after amenorrhea 11 
 12 
 13 
















TABLE OF CONTENTS  28 
Introduction  29 
Methods  30 
Methodological details of included studies 31 
Results  32 
Definition and diagnosis of functional hypothalamic amenorrhea (FHA) 33 
Diagnostic criteria for resumption of menses 34 
Causes of FHA and return of menses  35 
Potential mechanisms underlying the return of menses  36 
Treatment options trailed for re-onset and maintenance of menstruation 37 
Discussion  38 

















BACKGROUND: Prolonged amenorrhea occurs as a consequence of functional hypothalamic amenorrhea 54 
(FHA) which is most often induced by weight loss, vigorous exercise or emotional stress. Unfortunately, 55 
removal of these triggers does not always result in the return of menses. The prevalence and conditions 56 
underlying the timing of return of menses vary strongly and some women report amenorrhea several 57 
years after having achieved and maintained normal weight and/or energy balance. A better 58 
understanding of these factors would also allow improved counselling in the context of infertility. 59 
Although body mass index (BMI), percentage body fat, and hormonal parameters are known to be 60 
involved in the initiation of the menstrual cycle, their role in the physiology of return of menses is currently 61 
poorly understood. We summarize here current knowledge on the epidemiology and physiology of return 62 
of menses. 63 
OBJECTIVE AND RATIONALE: To provide an overview of (i) factors determining the recovery of menses and 64 
its timing, (ii) how such factors may exert their physiological effects, and (iii) whether there are useful 65 
therapeutic options to induce recovery. 66 
SEARCH METHODS: We searched articles published in English, French or German language containing 67 
keywords related to return of menses after FHA published in PubMed between 1966 and December 2019. 68 
Manuscripts reporting data either on the epidemiology or on the physiology of recovery of menses were 69 
included and bibliographies were reviewed for further relevant literature. The Strengthening the 70 
Reporting of Observational Studies in Epidemiology (STROBE) criteria served to asses quality of 71 
observational studies.  72 
OUTCOMES: Few studies investigate return of menses and most of them have serious qualitative and 73 
methodological limitations.  These include (i) the lack of precise definitions for FHA or resumption of 74 
menses, (ii) the use of short observation periods with unsatisfactory descriptions, and (iii) the inclusion of 75 
poorly characterized small study groups. The comparison of studies is further hampered by very 76 
inhomogeneous study designs. Consequently, the exact prevalence of resumption of menses after FHA is 77 
unknown. Also, the timepoint of return of menses varies strongly and reliable prediction models are 78 
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lacking. While weight, body fat and energy availability are associated with the return of menses, 79 
psychological factors also have a strong impact on the menstrual cycle and behavior known to increase 80 
the risk for FHA. Drug therapies with metreleptin or naltrexone might represent further opportunities to 81 
increase chances for the return of menses, but require further evaluation.  82 
WIDER IMPLICATIONS: Although knowledge on the physiology of return of menses is presently 83 
rudimentary, available data indicate the importance of BMI/ weight (gain), energy balance, and mental 84 
health. The physiological processes and genetics underlying the impact of these factors on the return of 85 
menses requires further research. Larger prospective studies are necessary to identify clinical parameters 86 
for accurate prediction of return of menses as well as reliable therapeutic options. 87 
 88 
KEY WORDS: Recovery of menses; return of menses; restoration of the menstrual cycle; weight; BMI; 89 




The human menstrual cycle is not only essential for reproduction but also for general well-being (Walf 92 
and Frye 2006). Estradiol is needed for adequate bone, cardiovascular, mental, and vaginal health (Levin, 93 
Jiang, and Kagan 2018; Iorga et al. 2017; Manonai, Chittacharoen, and Theppisai 2004; Rettberg, Yao, and 94 
Brinton 2014; Filova et al. 2015; Gordon et al. 2017). Weight loss, eating disorders, exercise, and 95 
emotional stressors suppress the activity of the GnRH neuronal network and to produce functional 96 
hypothalamic amenorrhea (FHA) (Drew 1961; Mecklenburg et al. 1974; Gadpaille, Sanborn, and Wagner 97 
1987; Berga and Girton 1989; Fries, Nillius, and Pettersson 1974; Frisch and McArthur 1974; Pirke et al. 98 
1989; Warren et al. 1999; Sanchez-Garrido and Tena-Sempere 2013; Roa et al. 2010; Castellano and Tena-99 
Sempere 2016; Garcia-Garcia 2012; Berga and Naftolin 2012; Bullen et al. 1985; Loucks et al. 1989). A 100 
reduction in GnRH drive results in abnormal LH pulse frequency generating cycle disturbances (Berga and 101 
Girton 1989; Laughlin, Dominguez, and Yen 1998; Ackerman et al. 2012). By definition, FHA is only 102 
diagnosed after anatomic or organic causes of amenorrhea have been excluded.  103 
 104 
FHA is responsible for 20–35% of secondary amenorrhea (American Society for Reproductive Medicine 105 
2008). It occurs in up to 89% of women with anorexia nervosa and up to 60% of high-performance athletes 106 
(Andersen and Ryan 2009; Watson and Andersen 2003; Roupas and Georgopoulos 2011; Sanborn, Martin, 107 
and Wagner 1982; Warren and Perlroth 2001). Because of pre-existing cycle irregularities, the concept of 108 
post-pill amenorrhea was abandoned in the early 80ies (Barnhart and Schreiber 2009; Jacobs et al. 1977); 109 
97% of women experience return of menses within a median time of 32 days after discontinuation of 110 
combined oral contraceptives (Davis et al. 2008).  111 
 112 
FHA is currently treated symptomatically by hormonal replacement therapy to prevent unfavourable 113 
health consequences resulting from a lack of estrogens. However, hormone therapy may be associated 114 
with an increased risk for breast cancer, venous thromboembolism or stroke (Marjoribanks et al. 2017; 115 
Magliano et al. 2006; Collaborative Group 2019). Infertility in FHA women is presently treated with timed 116 
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intercourse, intrauterine inseminations or IVF/ICSI and, while highly effective, the latter are costly, time-117 
consuming, and burdensome (Katz et al. 2011).  118 
 119 
To improve counselling and provide guidance for future research, this review summarizes available 120 
knowledge on the factors allowing the return of menses. While focussed primarily on clinical data, we 121 
also include a review of the mechanistic and translational aspects of anovulation and the return of menses 122 
gained from animal studies. We evaluate (i) which factors determine the recovery of menses and its 123 
timing, (ii) how these factors exert their physiological effects, and (iii) whether there are any useful 124 
therapeutic options to induce recovery. 125 
 126 
Method 127 
A systematic review of epidemiological data on resumption of menses in humans was performed in 128 
accordance with PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) criteria 129 
(Liberati et al. 2009). A PubMed search from 1966 to February 2020 included the MeSH terms: “re-onset/ 130 
return or recovery of menses/menstruation”, “anovulation”, “amenorrhea”, combined with, 131 
“hypothalamus”, “pituitary”, “gonadotropin releasing hormone (GnRH)”, “GnRH pulse generator”, 132 
“leptin”, “ghrelin”, “glucose”, “insulin”, “cortisol”, “kisspeptin” AND/ OR “influencing factors”, “body 133 
weight”, “energy balance”, “eating disorders”, “nutrition”, “diet”, “sports”, “stress”, “mental health”, 134 
“posttraumatic stress disorder (PTSD)”, “genetics” and/or “treatment”, “medication”, “stress 135 
management”, “psychotherapy”, “cognitive behavioural therapy (CBT)”. A “return of menses” set 136 
element AND/ OR a “factor/ physiology” set element were always included in title, abstract or all fields, 137 
where capital letters indicate Boolean connectors. All studies were screened by title and abstract. Eligible 138 
articles in English, German and French were read, and the relevant information was extracted. Secondary 139 




FHA is considered to be chronic anovulation not due to any identifiable anatomic or organic causes, i.e. it 142 
is a diagnosis of exclusion without any generally accepted diagnostic criteria (Bomba et al. 2007; Gordon 143 
2010; Gordon et al. 2017; Genazzani et al. 2010; Sowinska-Przepiera et al. 2015). The differential diagnosis 144 
between amenorrhea and FHA please has recently been reviewed (Gordon et al. 2017). Polycystic ovary 145 
syndrome (PCOS) was considered a diagnosable cause of amenorrhea and therefore not included within 146 
the present review. 147 
Any study reporting at least one menstruation after a phase of FHA was considered within this review. 148 
The initial systematic search yielded a total of 1424 manuscripts published between 1966 and February 149 
2020, with forty-nine manuscripts directly addressing either recovery of menses (N = 34) or prolonged 150 
amenorrhea (N = 15) in humans. Prospective (N = 23) and cross-sectional studies (N = 13) investigating 151 
between 12 and 463 participants formed the majority of research. In addition, five retrospective, six case-152 
control studies and two case reports were analysed.  153 
Quality of observational studies was assessed using the “Strengthening the Reporting of Observational 154 
Studies in Epidemiology” (STROBE) criteria (von Elm et al. 2007). Case reports were evaluated by the 155 
Consensus-based Clinical Case Reporting Guideline Development (CARE) Guidelines (Gagnier et al. 2013).  156 
 157 
Animal studies investigating the neural mechanisms underlying the impact of metabolic factors on the 158 
reproductive axis were considered by AEH. To ensure, no major paper was omitted, recent reviews on the 159 
subject from three different research groups were consulted (Ronnekleiv, Qiu, and Kelly 2019; Vazquez, 160 
Velasco, and Tena-Sempere 2019; Chianese et al. 2018; Evans and Anderson 2017). 161 
 162 
Methodological details of included studies 163 
Resumption of menses and/or risk factors for prolonged amenorrhea were investigated predominantly 164 
after the treatment of eating disorders (N = 29), but also in athletes (N = 13) or in stress-related FHA (N = 165 
7). Most studies compared anthropometric data (body weight, BMI, body fat) or hormonal parameters 166 
between women with and without return of menses aged < 30 years. Out of the 34 studies directly 167 
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investigating the recovery of menses, twelve controlled for well-known hormonal causes of cycle 168 
disturbances and related diseases such as PCOS, thyroid diseases, hyperprolactinemia, adrenogenital 169 
syndrome, disturbances of the adrenal and pituitary gland or premature ovarian insufficiency. The 170 
underlying pathophysiology and the timeline of recovery of menses was rarely addressed. Of the 47 171 
observational studies, 13 were of low, 29 of medium, and 5 of high quality (von Elm et al. 2007). The 172 
quality of case reports was middle (Kopp-Woodroffe et al. 1999) to high (Mallinson et al. 2013). 173 
 174 
Results  175 
We first define the diagnostic criteria for FHA and the resumption of menses before summarizing the 176 
causes of FHA, as their reversal may play a role in the return of menses. We next address potential physical 177 
and psychological mechanisms involved in the onset and end of FHA including their interactions. Finally, 178 
we will give an overview of currently available treatment options. 179 
 180 
Diagnosis of functional hypothalamic amenorrhea (FHA) 181 
To diagnose FAH, 16 studies relied solely on self-reported amenorrhea (Table 1) while 30 studies 182 
evaluated initial cycle status by serum (estradiol, FSH and LH) or urine (estrone glucuronide, pregnanediol 183 
glucuronide and LH) hormonal parameters. Transvaginal ultrasound of the ovaries was performed in four 184 
studies and radiography of the sella turcica in one (Falsetti et al. 2002). A positive response to a GnRH 185 
stimulation test was another diagnostic criterion (Pentz and Nakic Rados 2017). FHA was diagnosed after 186 
at least three (16 studies) or six (8 studies) months of amenorrhea. Further prerequisites for the diagnosis 187 
of FHA were regular menses prior to FHA (Sterling et al. 2009; Christo et al. 2008) or a coincidence of 188 
amenorrhea with increased exercise or low weight (Welt et al. 2004). Four studies provided no specific 189 
definition of FHA (Bodell and Mayer 2011; Chou et al. 2011; Holtkamp et al. 2003; Rigaud et al. 2011). 190 
 191 
Diagnostic criteria for resumption of menses 192 
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The majority of studies (N = 24) did not provide any definition of resumption of menses (Table 1). Of the 193 
34 studies explicitly addressing resumption of menses, 31 relied on self-reported bleeding with 12 194 
differentiating between one, two or three consecutive spontaneous menstrual cycles as cut-off to 195 
diagnose recovery of menses. Four studies required a cycle length of less than 36 days to diagnose 196 
recurrence of menses. Further criteria were the exclusion of other potential causes of vaginal bleeding 197 
such as infection or trauma. Six studies evaluated either with urine / serum hormonal parameters or by 198 
ultrasound whether menstrual cycles were ovulatory.  199 
 200 
Body weight, energy availability and return of menses 201 
The association between body weight/ energy availability and return of menses was explored in eating 202 
disorders, or in the context of physical activity (Table 2 and 3, Fig. 1). The majority of the 19 studies 203 
support that anthropometric characteristics i.e. BMI, body weight or body composition are associated 204 
with resumption of menses (Table 2). However, there are also opposite results (Arimura et al. 2010; El 205 
Ghoch et al. 2016).  206 
 207 
Eating disorders, body weight and energy availability 208 
Patients who resume menses after eating disorders have a higher BMI (19 kg/m2 vs 17.5 kg/m2) or body 209 
weight  than those who do not (Dempfle et al. 2013; Le Grange et al. 2012). As with individual differences 210 
at the onset of amenorrhea, the individual BMI for recovery of menses differs strongly and comparison of 211 
different studies is hampered by the use of different weight measures. For example, two-thirds of 212 
anorectic girls became amenorrheic at a BMI between 17 and 18.9 kg/m2 while the remaining third had a 213 
normal BMI (Berner et al. 2017). A higher BMI at the onset of amenorrhea is associated with a higher BMI 214 
needed to allow return of menses (Berner et al. 2017; Pitts et al. 2014). At or above a BMI of 19 kg/m2 215 
and ≥ 23% body fat, about 50% of women are expected to resume menses (Tinahones et al. 2005). Women 216 
with a BMI of 14 kg/m2 and 11% body fat still had a probability of 25% for recovery of menses (Winkler et 217 
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al. 2017). Generally, recovery of menses seems to require about 2kg more than the weight of the woman 218 
at the time at which menses were lost (Golden et al. 1997).   219 
 220 
Using other weight parameters, menstrual recovery was reported to occur at 91.6 ± 9.1% of standard 221 
body weight (median body weight adjusted for age, gender, frame size and height) (Frisancho 1984) of 222 
(Golden et al. 1997) or 94.9 ± 9.3% of expected body weight (EBW = optimal weight related to height 223 
and/or age for healthy nutritional status with the lowest rate of mortality) (Faust et al. 2013). In anorectic 224 
postmenarcheal girls, a BMI ≥ 27th percentile based on percentiles derived from different national health 225 
surveys or a BMI at the 24th percentile based on BMI measurements from 17 German studies, seems to 226 
be necessary for recovery of menses (Dempfle et al. 2013; Golden et al. 2008; Kuczmarski et al. 2000). 227 
Interestingly, during spring or summer, anorectic women needed on average 2 kg less for resumption of 228 
menses than during fall or winter (Favaro and Santonastaso 2009).  229 
 230 
According to prospective data from anorectic patients, the onset and regularity of menstrual cycles 231 
requires between 18% and 28% of body fat (El Ghoch et al. 2016; Frisch and McArthur 1974; Frisch 1987; 232 
Karountzos et al. 2017; Misra et al. 2006; Tokatly Latzer et al. 2019; Winkler et al. 2017; Pitts et al. 2014) 233 
(Table 2). However, even with 36% body fat, not all women resumed menses (Tinahones et al. 2005). An 234 
increase of about 1% in total body fat at discharge after anorexia treatment was reported to augment the 235 
probability of menses by approximately 14% per year (El Ghoch et al. 2016). Modifications in fat 236 
distribution following weight recovery seem to be irrelevant for resumption of menses (Dei et al. 2008; 237 
Mayer et al. 2009).  238 
Independent from absolute weight, dieting is considered to be a risk factor for amenorrhea (Martini et al. 239 
2016). After at least one year of stable normal weight, caloric intake still differed significantly between 240 
women with persisting FHA and age-, weight-, as well as body fat- matched control women with a regular 241 
cycle (Miller et al. 1998). In addition, eating disorders are closely associated with stress (Smith et al. 2018; 242 
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Keski-Rahkonen and Mustelin 2016), which may further increase the risk for prolonged amenorrhea (see 243 
below).  244 
A few studies have reported no significant association between body fat and the return of menses 245 
(Arimura et al. 2010; Golden et al. 1997; Dei et al. 2008; Jacoangeli et al. 2006). Arimura and colleagues 246 
(Arimura et al. 2010) reported no resumption of menses immediately after weight recovery but this may 247 
have been too short a period of observation as studies supporting an association are based on a longer 248 
follow-up period (El Ghoch et al. 2016; Misra et al. 2006; Karountzos et al. 2017; Pitts et al. 2014; Tokatly 249 
Latzer et al. 2019). Golden and co-workers (Golden et al. 1997) applied skinfold thickness measurements, 250 
which are of rather limited diagnostic quality to evaluate body fat (El Ghoch et al. 2012). The cross-251 
sectional studies reporting no association were either small (Jacoangeli et al. 2006) or applied an arbitrary 252 
definition of weight recovery (Dei et al. 2008). 253 
In summary, the absolute BMI has to be between 17.7±1.4 kg/m2 (Pitts et al. 2014) and 22.9±2.5 254 
kg/m2 (Cialdella-Kam et al. 2014) and body fat between 18% and 28% to allow resumption of menses. The 255 
BMI at occurrence of amenorrhea is important in setting the individual weight target for recovery of 256 
menses. As current research on the association between eating disorders has focused on weight, 257 
information is lacking on whether specific eating disorder-related malnutrition is related to amenorrhea.   258 
 259 
Prognosis and timing of return of menses after weight recovery: Between 35% and 54% of women 260 
experience return of menses immediately after achieving normal weight (Arimura et al. 2010; Dempfle et 261 
al. 2013; El Ghoch et al. 2016; Winkler et al. 2017; Bodell and Mayer 2011). After a longer 262 
treatment/observation period, these rates may rise to 80% or even 100% (Golden et al. 1997; Kohmura 263 
et al. 1986; Jacoangeli et al. 2006; Tinahones et al. 2005) (Table 3). Studies providing exact information 264 
on the time to recovery of menses after weight restoration reported a broad range from 50 ± 33 days up 265 
to 14 ± 12 months until the return of menses (Arimura et al. 2010;  Faust et al. 2013; Golden et al. 1997; 266 
Karountzos et al. 2017; Swenne 2004;  Tinahones et al. 2005; Tokatly Latzer et al. 2019).  267 
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Between 5% and 68% of women have been reported to remain amenorrheic after weight recovery 268 
(Dempfle et al. 2013; El Ghoch et al. 2016; Golden et al. 1997; Karountzos et al. 2017; Jacoangeli et al. 269 
2006; Tokatly Latzer et al. 2019; Favaro and Santonastaso 2009; Misra et al. 2006; Pitts et al. 2014; 270 
Kohmura et al. 1986) with between 5% and 14% ultimately remaining amenorrheic (Golden et al. 1997; 271 
Jacoangeli et al. 2006).  272 
According to the guidelines of the Endocrine Society, “the term “functional” hypothalamic amenorrhea 273 
implies that correction or amelioration of the causal factors will restore ovulatory ovarian function” 274 
(Gordon et al. 2017). However, the return of menses does not necessarily occur after such correction. In 275 
previously anorectic adolescents, 86% experienced the return of menses within six months of stable 276 
weight (Jacoangeli et al. 2006). After one year of successful treatment against anorexia, 35% - 68% of 277 
women resumed menses and 95% had recovered by year two (Dempfle et al. 2013; El Ghoch et al. 2016; 278 
Golden et al. 1997; Golden et al. 2008; Abbate Daga et al. 2012; Bodell and Mayer 2011; Faust et al. 2013; 279 
Misra et al. 2006). As all adolescents with premenarchal onset of anorexia remained amenorrheic at the 280 
12-month follow-up following weight restoration, the premenarchal onset of eating disorders seems to 281 
be an unfavourable factor for recovery of menses (Dempfle et al. 2013). About 5% of previously anorectic 282 
adolescents remain amenorrheic two years after achieving normal weight (Golden et al. 1997). In the 283 
study with the longest observation period of 13 years, 97% of anorectic women resumed their menses 284 
(Rigaud et al. 2011). In that study, a BMI >18.5 kg/m2 and lack of physical hyperactivity explained 67% of 285 
the variance in return of menses. 286 
Although return of menses clearly depends on prerequisites such as BMI or energy availability, individual 287 
recovery is difficult to predict. None of the available mathematical models succeed in predicting the exact 288 
time for return of menses. Percent body fat and BMI have equal predictive quality but explain only 14% 289 
of the variation in recovery of menses (Winkler et al. 2017).  290 
 291 
Excessive exercise, body weight and energy availability  292 
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Total absolute and percentage weight gain, as well as BMI, are found to differ between athletes with and 293 
without recovery of menses (Arends et al. 2012). Nutrition and energy balance also play a role in the 294 
return of menses; amenorrheic athletes eat less fat but more carbohydrates and fiber than those with a 295 
normal menstrual cycle (Laughlin, Dominguez, and Yen 1998; Cialdella-Kam et al. 2014). Energy availability 296 
(defined as the net input of energy remaining after exercise training and energy needed for all other 297 
metabolic processes, normalized to kg of lean body mass (Loucks and Thuma 2003)) is lower in 298 
amenorrheic than in eumenorrheic exercising women (Williams et al. 2001), but does not differentiate 299 
between ovulatory and anovulatory cycles (Reed et al. 2015). Athletes with amenorrhea often consume 300 
too few calories for their energy needs (Melin et al. 2016; Elliott-Sale et al. 2018) and the likelihood of 301 
exercise-related menstrual abnormalities seems to vary with the magnitude of the energy deficit 302 
(Williams et al. 2015). LH pulsatility has been reported to be disrupted when energy intake in women is 303 
less than 30 kcal/kg lean body weight per day (Loucks and Thuma 2003; Loucks, Kiens, and Wright 2011; 304 
Dueck et al. 1996; Reed et al. 2015). Also, an overall reduction of energy by 470 and 810 kcal per day in 305 
women with an initial body fat between 15–35% and a BMI 18–25 kg/m2 increases the risk for menstrual 306 
cycle disturbances (Williams et al. 2015). Menstrual function may already stop at energy availabilities 307 
above this threshold, but specific causes for these differences have not be identified as yet (Lieberman et 308 
al. 2018; Reed et al. 2015; Holtzman and Ackerman 2019). It is possible that age-related physiological 309 
differences during adolescence may influence actual parameter thresholds. However, very few studies 310 
have so far addressed the identification of clear cut-off values and related influencing factors. 311 
Unfortunately, the exact extent of physical activity and details of nutrition and nutritional supplements 312 
are only assessed in a few studies, which makes comparison of results difficult. 313 
Athletes with FHA also show a significantly lower resting energy expenditure compared to eumenorrheic 314 
athletes, but part of this difference may result from discrepancies in initial and actual body weight or BMI 315 




Prognosis and timing of the return of menses after adjusting energy and weight: Weight gain or increased 318 
energy availability by nutritional supplements, and a decrease in energy expenditure, increases the 319 
chances for resumption of menses (Table 3) (Arends et al. 2012; Cialdella-Kam et al. 2014; Kopp-320 
Woodroffe et al. 1999; Lagowska et al. 2014; Mallinson et al. 2013). In athletes close to normal weight, 321 
amenorrhea may reverse when training is reduced (Benson, Engelbert-Fenton, and Eisenman 1996; 322 
Warren 1980). With adequate calorie-intake, menses are expected to reoccur in 75% – 100% of women 323 
(Kopp-Woodroffe et al. 1999; Mallinson et al. 2013; Cialdella-Kam et al. 2014). An appropriately balanced 324 
diet with the simultaneous limitation of training volume and intensity is therefore the main tool to reduce 325 
menstrual disorders in athletes (Nattiv et al. 2007; Manore, Kam, and Loucks 2007) with percent weight 326 
gain being a significant positive predictor for recovery of menses (Cialdella-Kam et al. 2014).  327 
After adjusting weight and energy balance, the time until recovery of menses varied from 11 weeks to 33 328 
months (Arends et al. 2012; Cialdella-Kam et al. 2014; Kopp-Woodroffe et al. 1999; Mallinson et al. 2013). 329 
While one study showed a correlation between the duration of amenorrhea and recovery of menses 330 
(Cialdella-Kam et al. 2014), another study did not support such association (Arends et al. 2012).  331 
 332 
Comparison of women with eating disorders to women with excessive exercise 333 
The relevance of different factors involved in the resumption of menses seems to vary in relation to 334 
factors involved in the initiation of amenorrhea. In eating disorders, the extent of weight and/or fat gain 335 
seems to be particularly important for recovery (El Ghoch et al. 2016; Dempfle et al. 2013) whereas in 336 
normal-weight athletes, adequate energy intake seems to play the major role (Reed et al. 2015). Women 337 
with eating disorders show addictive and obsessive-compulsive traits, that can manifest in excessive 338 
physical activity (Davis and Claridge 1998). Amenorrhea is more prevalent among athletes with eating 339 
disorders (Peric et al. 2016), and 39%–48% of women with eating disorders also engage in excessive 340 
exercise, i.e. there is a common overlap of risk factors for prolonged amenorrhea (Freimuth, Moniz, and 341 




Potential mechanisms underlying the return of menses  344 
Body weight and energy availability 345 
There is a well-documented regulatory influence of energy balance on fertility. For the most part this is 346 
brought about by circulating energy-related hormones and metabolites that modulate the functioning of 347 
central hypothalamic networks controlling the secretion of gonadotropin-releasing hormone (GnRH). 348 
Mammalian fertility is governed by a neural network that integrates a range of internal and external cues 349 
to control the release of GnRH that, in turn, generates pulsatile and surge profiles of gonadotropin 350 
secretion (Fig. 2) (Herbison 2016). Although pulsatile gonadotropin secretion occurs throughout the 351 
menstrual cycle, the frequency and amplitude of pulses change across the cycle to ensure the correct 352 
maturation of developing follicles (Herbison 2018). Studies in animal models have now demonstrated that 353 
a population of kisspeptin neurons located in the hypothalamic arcuate/infundibular nucleus operate as 354 
the “GnRH pulse generator” by activating the GnRH neurons to generate pulsatile gonadotropin secretion 355 
(Herbison 2018; Plant 2019). It is clear from both animal and human studies that chronic and acute 356 
energetic stressors can result in a marked reduction in LH pulsatility (Loucks, Verdun, and Heath 1998; 357 
Hilton and Loucks 2000; Wade and Jones 2004; Loucks and Thuma 2003). In addition to pulses, the 358 
hypothalamus and pituitary generate the mid-cycle LH surge that initiates ovulation. Disturbances of 359 
either pulsatile or surge profiles of gonadotropin hormone secretion can suppress fertility.  360 
  361 
Investigators have now discovered a wide range of circulating factors that inform the brain on the 362 
metabolic and energy status of the body. Whilst these hormones are primarily driving appropriate central 363 
energy regulation through appetite and energy expenditure, the same signals are thought to be used to 364 
regulate the GnRH neuron network and, accordingly, the menstrual cycle (Evans and Anderson 2017; 365 
Fernandez-Fernandez et al. 2006; Navarro and Kaiser 2013). Discussed below are the roles of leptin, 366 
ghrelin and insulin, considered to be the primary peripheral factors signalling information on body weight 367 
and energy availability to the GnRH neuron network. The impact of activating stress pathways, often not 368 




The vast majority of work in this field has examined how energy insufficiency/stress operates to suppress 371 
pulsatile gonadotropin secretion resulting in cycle abnormalities and infertility. Unfortunately, very little 372 
work has examined the return of fertility with the presumption being that it is a reversal of the mechanism 373 
that initiates the infertility generated by energy stress. Perhaps surprisingly, the resumption of pulsatile 374 
LH secretion in re-fed, acutely energetically-stressed women is much slower (taking up to one week) than 375 
in men or in experimental animals examined to date (Loucks, Verdun, and Heath 1998; Cameron 1996; 376 
Szymanski et al. 2007). 377 
 378 
Leptin: Secreted by adipocytes into the circulation, leptin signals body fat stores with elevated levels 379 
acting on the hypothalamus to reduce feeding and increase energy expenditure. Leptin concentrations 380 
also fluctuate on a shorter time scale unrelated to weight or body fat, being reduced with fasting (Ahima 381 
et al. 1996; Flier 1998; Grinspoon et al. 1997). Women with anorexia and exercise-induced amenorrhea 382 
are hypoleptinemic (Audi et al. 1998; Jimerson et al. 2000; Mantzoros et al. 1997; Miller et al. 1998). 383 
Interestingly, even after controlling for body fat, women with exercise- or eating-related FHA have 384 
significantly lower leptin levels than those of their ovulatory counterparts (Miller et al. 1998; Warren et 385 
al. 1999; Andrico et al. 2002). A leptin level of 1.85 ng/ml (Reference 4.1 – 25 ng/ml) appears to be the 386 
critical level for amenorrhea (Kopp et al. 1997).  Values above this lead to an increase of LH (Holtkamp et 387 
al. 2003) and more than 20% of amenorrheic women recover menses at levels > 1.85 ng/ml  (Tinahones 388 
et al. 2005). However, a cross-sectional study found no differences in leptin levels or BMI between two 389 
groups of anorectic patients with and without amenorrhea (Audi et al. 1998). Furthermore, the 390 
reinstatement of pulsatile LH secretion by refeeding chronically food-restricted ewes was found to be 391 
unrelated to circulating leptin concentrations (Nakamura, Osonoi, and Terauchi 2010). 392 
The mechanisms through which leptin controls fertility are multifaceted and may involve peripheral as 393 
well as central actions. For example, high leptin levels enhance oocyte nuclear and cytoplasmic 394 
maturation and affect follicle rupture and corpus luteum formation (Craig et al. 2004; Ruiz-Cortes et al. 395 
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2003). However, studies in rodents indicate that the primary impact of leptin on fertility likely arises 396 
through central mechanisms. The deletion of leptin receptors from just the brain results in infertility 397 
(Quennell et al., 2009) and actively blocking leptin signalling in the brain reduces pulsatile LH secretion 398 
(Carro et al., 1997). These effects are often considered to be permissive in the sense that they enable 399 
normal functioning of the GnRH neuron network rather than actually determining its magnitude or mode 400 
of action.  401 
Many studies in animal models have tried to establish the neural pathway through which leptin influences 402 
GnRH neurons. As GnRH and kisspeptin neurons seem unlikely to express functionally significant leptin 403 
receptors themselves, attention has focussed upon indirect mechanisms by which circulating leptin 404 
modulates the activity of neurons that project to and control the kisspeptin and/or GnRH neurons (Evans 405 
and Anderson 2017; Navarro and Kaiser 2013). While roles have been proposed for leptin to operate 406 
through premammilary nucleus neurons (Donato et al. 2011) and GABA neurons in the brain (Zuure et al. 407 
2013) to control GnRH secretion, most evidence favours an effect of leptin on neuropeptide Y/agouti-408 
related peptide (NPY/AgRP) neurons (Ronnekleiv, Qiu, and Kelly 2019). These are the same cells 409 
implicated in the potent actions of leptin on energy metabolism. As such, it is envisaged that low leptin 410 
levels act through NPY/AgRP neurons to both increase feeding and disable the normal menstrual/estrous 411 
cycle. Precisely how the leptin-sensing NPY/AgRP neurons impact upon GnRH secretion remains unclear 412 
with the most likely pathway being through direct the control of the kisspeptin neuron pulse generator 413 
(Hessler, Liu, and Herbison 2020). The resumption of menses in FHA woman may result from the re-414 
establishment of normal energy balance leading to normalised leptin levels and consequently reduced 415 
NPY/AgRP neuron activity permitting normal pulsatile GnRH secretion.  416 
 417 
Insulin & glucose: Diet and negative energy balance associated with FHA generate a hypometabolic state 418 
that includes, among other abnormalities, lowered circulating insulin levels (Laughlin and Yen 1996). As 419 
such, insulin is one potential pathway through which the menstrual cyclicity is regulated in women with 420 
exercise- or diet-related FHA. Indeed, fasting insulin levels are higher in women with a history of eating 421 
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disorders after return of menses compared to women remaining amenorrheic (Dei et al. 2008; Karountzos 422 
et al. 2017; Tinahones et al. 2005). A similar association has been confirmed following weight-recovery 423 
(defined as an increase in weight >85% of the initial weight before amenorrhea) (Dei et al. 2008), during 424 
the 8 - 26 months treatment phase for an eating disorder (Karountzos et al. 2017) and in the early follicular 425 
phase in women with resumption of menses (Tinahones et al. 2005). However, studies in male monkeys 426 
indicate that the key factor underlying the return of normal LH pulsatility following a nutritional stress is 427 
the increase in caloric intake independent of glucose or insulin (Cameron 1996). 428 
It is likely that insulin operates at multiple levels of the reproductive axis to exert a modulatory effect 429 
upon fertility. Unlike leptin, there is much less certainty that insulin actions in the brain are necessary or 430 
critical. Whereas an early study reported that the deletion of insulin receptors selectively from the brain 431 
of mice resulted in mild hypogonadism (Bruning et al. 2000), another study found no reproductive 432 
abnormalities (Evans and Anderson 2017). Further, the deletion of insulin receptors selectively from GnRH 433 
or kisspeptin neurons, or a range of other neuronal phenotypes, has been found to have no impact upon 434 
fertility in mice (Qiu et al. 2013; Divall et al. 2010; Evans and Anderson 2017). Interestingly, over nutrition 435 
resulting in obesity-induced infertility in mice appears to be dependent, at least in part, upon insulin 436 
signalling at the GnRH neuron (Divall et al. 2010), pituitary gland (Brothers et al. 2010) and ovary (Wu et 437 
al. 2012). It is unknown whether this represents a similar mechanism to the cycle disturbances resulting 438 
from energy deficit.  439 
Glucose concentrations themselves may represent an independent pathway through which energy stress 440 
suppresses the menstrual cycle. For example, reducing glucose availability within the brain suppresses 441 
pulsatile LH secretion in experimental animals (Murahashi et al. 1996; Lado-Abeal et al. 2002) and binge 442 
eating or binge-purge behaviour in humans is associated with a higher risk for FHA (Johnson and Whitaker 443 
1992). Differentiating any role of glucose from insulin in energy stress-evoked FHA can be challenging, but 444 
available evidence is equivocal regarding whether glucose may be more or less important than alterations 445 
in insulin secretion (Roland and Moenter 2011; Szymanski et al. 2007; Cameron 1996). Precisely where 446 
glucose acts to modulate the menstrual cycle remains unclear given the ubiquitous requirement for 447 
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glucose and multiple different sensors that could be involved. Peripherally, glucose deficiency can 448 
compromise the ability of the oocyte to reach the second metaphase, to extrude the first polar body 449 
(Dominko and First 1997), and to achieve the blastocyte stage (Dan-Goor et al. 1997). There is also 450 
evidence demonstrating that glucose modulates the electrical excitability of GnRH neurons in a direct 451 
manner through AMPkinase, as well as indirectly through glucose-sensitive inputs from neurons located 452 
in the brainstem (Roland and Moenter 2011). Thus, the return of a normoglycemic state to women with 453 
FHA may contribute to the return of menses through direct glucose actions at multiple and varied sites 454 
throughout the reproductive axis. 455 
 456 
Ghrelin: Ghrelin acts as a signal of starvation and energy insufficiency and is secreted by the stomach in a 457 
fluctuating pattern with elevated concentrations occurring prior to meals (Tena-Sempere 2013). 458 
Unsurprisingly then, ghrelin concentrations are found to be continuously elevated in women suffering 459 
from chronic undernutrition and exercise-induced amenorrhea (De Souza et al. 2004; Schneider, Monaco, 460 
and Warren 2008; Tolle et al. 2003; Christo et al. 2008). In this case, an energy deficient state results in 461 
elevated ghrelin levels (compared with reduced leptin, insulin and glucose concentrations) and evidence 462 
indicates that elevated ghrelin levels suppress gonadotropin secretion (Kluge et al. 2012). Hence, the 463 
elevated ghrelin levels found in women with FHA may represent another pathway contributing to their 464 
suppressed fertility (Christo et al. 2008).  465 
In common with the other potential hormonal mediators highlighted above, ghrelin has multiple potential 466 
sites of action within the reproductive axis. Ghrelin receptors (GHS-R) are widely expressed in the ovary, 467 
pituitary and within the regions of the hypothalamus involved in the control of GnRH secretion (Gaytan 468 
et al. 2003; Gaytan et al. 2005; Tena-Sempere 2007). However, animal studies indicate that ghrelin 469 
signalling is not itself essential for the suppression of cycles as the deletion of the ghrelin receptor in mice 470 
has no impact on fertility or feeding (Sun, Ahmed, and Smith 2003). It does, however, appear to modulate 471 
glucose sensing, insulin sensitivity and the stress response (Sun et al. 2008; Sominsky et al. 2017) and may, 472 
through these mechanisms, have some role in indirectly modulating the menstrual/estrous cycle (Evans 473 
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and Anderson 2017).  474 
 475 
Other hormones: While the discussion above considers what are thought to be the primary hormonal 476 
signals modulating fertility, women with energy-related FHA exhibit multiple other endocrine 477 
abnormalities. For example, FT3, FT4, and TSH are commonly decreased in amenorrheic women with 478 
eating disorders and increase after resumption of menses (Dei et al. 2008; Karountzos et al. 2017; 479 
Tinahones et al. 2005). Whether and how thyroid hormones are related to the resumption of menses 480 
remains unclear. Similarly, levels of growth hormone and insulin-growth factor-1 (IGF1) are reduced in 481 
FHA (Bomba et al. 2007; Miller et al. 2004). An IGF-1 level of >342.8 ng/ml has been proposed to be a 482 
predictor for return of menses (Cominato et al. 2014), although two other studies have found no positive 483 
correlation (Falsetti et al. 2002; Arimura et al. 2010). 484 
 485 
Psychological and psychogenic factors  486 
The hypothalamic neurons regulating GnRH pulses not only respond to metabolic conditions but also to 487 
psychological and psychogenic factors (Drew 1961; Mecklenburg et al. 1974; Gadpaille, Sanborn, and 488 
Wagner 1987; Berga and Girton 1989; Fries, Nillius, and Pettersson 1974; Frisch and McArthur 1974; Pirke 489 
et al. 1989; Warren et al. 1999; Sanchez-Garrido and Tena-Sempere 2013; Roa et al. 2010; Castellano and 490 
Tena-Sempere 2016; Garcia-Garcia 2012; Berga and Naftolin 2012; Bullen et al. 1985; Loucks et al. 1989).  491 
Emotional stressors as measured by both subjective and objective parameters increase the risk for FHA in 492 
humans and in animals (Sanders and Bruce 1999; Gordley et al. 2000; Bomba et al. 2007; Brown et al. 493 
1983; Kondoh et al. 2001; Facchinetti et al. 1993; Harlow and Matanoski 1991). In adolescent girls, 494 
changing school, initiating sexual activity, breaking up with a boyfriend, chronic illness, death of a friend 495 
or family member, and family conflicts may result in FHA (Bomba et al. 2007). Psychological risk factors 496 
that chronically activate the HPA axis include perfectionism, high need for social approval, conditional 497 
love and/ or unrealistic expectations of self and others (Berga and Girton 1989; Giles and Berga 1993; 498 
Marcus, Loucks, and Berga 2001). College students who later became amenorrheic have been reported 499 
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to be more anxious, stubborn, and perfectionist (Shanan et al. 1965). It is possible that sleep deprivation 500 
may exacerbate this by further activating the HPA axis to induce anovulation and amenorrhea (Lateef and 501 
Akintubosun 2020). These effects are also seen in monkey models where a change of social environment, 502 
or disruptive social interactions with group members can generate amenorrhea (Michopoulos et al. 2009; 503 
Bethea, Centeno, and Cameron 2008; Bethea et al. 2005; Wagenmaker et al. 2009; Adams, Kaplan, and 504 
Koritnik 1985).  505 
Traumatic events such as sexual assault, incarceration or natural disasters may induce post-traumatic 506 
stress disorders (PTSD) (Beaglehole et al. 2018; Leeners et al. 2007), which is another risk factor for FHA 507 
(Berga and Girton 1989). For example, FHA has been reported after floods (Neuberg et al. 1999) and in 508 
women interned in a concentration camp during the Second World War before any malnutrition became 509 
evident (Sydenham 1946). Incarcerated women show a higher prevalence of amenorrhea, with women 510 
reporting additional stress factors such as childhood physical or sexual abuse, economic deprivation or 511 
coming from a racial and ethnic minority being at increased risk (Allsworth et al. 2007).  512 
It is also evident that behaviours such as over-exercise or restricting eating may reflect an underlying 513 
mental or psychiatric disease (Giles and Berga 1993; Marcus, Loucks, and Berga 2001; Berga 2008). For 514 
instance, amenorrheic runners were found to suffer significantly more often from  major affective or 515 
eating disorders than menstruating runners (Gadpaille, Sanborn, and Wagner 1987). Also women with 516 
anxiety disorders or depression have been found to be at increased risk for FHA (Fava et al. 1984; Joffe et 517 
al. 2006; Lawson et al. 2009). 518 
 519 
Women with FHA often display combinations of psychological factors that can activate stress responses, 520 
induce metabolic disturbances, and/or result in excessive exercising (Marcus, Loucks, and Berga 2001; 521 
Giles and Berga 1993; Faust et al. 2013). In rhesus monkeys, the combination of low-level psychosocial 522 
stress and moderate energy imbalance resulted in a higher proportion of abnormally long or anovulatory 523 
cycles than either stressor alone (Williams, Berga, and Cameron 2007; Williams et al. 2001). Thus, 524 
psychological, psychogenic and metabolic stressors act synergistically in compromising reproduction 525 
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(Marcus, Loucks, and Berga 2001; Giles and Berga 1993; Berga, Daniels, and Giles 1997; Warren et al. 526 
1999; Williams, Berga, and Cameron 2007; Berga 2008). In line with these findings, severe mental or 527 
infectious diseases such as HIV or Ebola infection have been found to add to the risk for FHA (Fava et al. 528 
1984; Cejtin et al. 2018; Godwin et al. 2019). On this background, the current SARS-CoV-2 pandemic will 529 
probably also influence the prevalence of FHA.  530 
 531 
Substantial investigation has focused on examining the mechanisms through which immune, nutritional 532 
and psychological stressors impact upon the reproductive axis (Li and O'Byrne 2015). Stress activates 533 
multiple neural axes and results in elevated corticosteroid and prolactin concentrations. All of these 534 
factors, in turn, can impact upon the functioning of the GnRH neuronal network (Li and O'Byrne 2015; 535 
Mastorakos, Pavlatou, and Mizamtsidi 2006; Meczekalski et al. 2008; Williams, Berga, and Cameron 2007; 536 
Berga and Girton 1989; Dobson et al. 2003). In many cases, it is difficult to tease apart the impacts of 537 
nutritional and psychological stressors on fertility with a synergism between the two in operation (Berga 538 
1997; Fioroni et al. 1994; Shanan et al. 1965; Chand and Lovejoy 2011; Mendelson 2013). 539 
 540 
Cortisol: High cortisol levels are well known to be associated with amenorrhea (Berga, Daniels, and Giles 541 
1997; Suh et al. 1988; Berga and Girton 1989; Brundu et al. 2006): Athletes with FHA as well as those with 542 
eating disorders and amenorrhea have higher serum cortisol levels than women with a menstrual cycle 543 
(Villanueva et al. 1986; Laughlin, Dominguez, and Yen 1998; Ackerman et al. 2012). Administration of 544 
hydrocortisone reduces LH pulse frequency during the follicular phase of otherwise eumenorrheic women 545 
(Saketos, Sharma, and Santoro 1993). Elevated circulating corticosteroids reduce LH pulse amplitude 546 
(Petraglia et al. 1987; Olster and Ferin 1987; Breen et al. 2008; Dudas and Merchenthaler 2002; Saketos, 547 
Sharma, and Santoro 1993) and suppress LH pulse frequency through an unknown central mechanism 548 
(Ralph et al. 2016). Traumatic family events (sexual abuse, parental conflict, separation or death) have are 549 
associated with elevated cortisol levels that can persist beyond the traumatic period (Flinn et al. 2011; 550 
Jacobs, Boynton-Jarrett, and Harville 2015) and consequently present a long-term risk factor for FHA.  551 
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Cortisol seems to be one of the most important factors in return of menses. In women with a history of 552 
eating disorders, and even after weight gain, serum levels of fasting cortisol tend to be lower in women 553 
with return of menses compared to those without (Dei et al. 2008; Karountzos et al. 2017; Misra et al. 554 
2006; Pitts et al. 2014; Tinahones et al. 2005; Arimura et al. 2010). Other studies confirmed significant 555 
differences in cortisol levels between women with and without return of menses (Falsetti et al. 2002; 556 
Jacoangeli et al. 2006; Miller et al. 1998) and two studies identified low serum cortisol levels as a predictor 557 
for the return of menses (Arimura et al. 2010; Falsetti et al. 2002). Furthermore, women with a return of 558 
menses after cognitive behavioral therapy had cortisol levels comparable to those of eumenorrheic 559 
women (Berga, Daniels, and Giles 1997).  560 
 561 
CRH: CRH suppresses pulsatile LH secretion but the pathway through which activated CRH neurons inhibit 562 
GnRH secretion remains unclear (McCosh, Breen, and Kauffman 2019; Li and O'Byrne 2015). There is little 563 
evidence for a direct modulation of GnRH neurons by CRH although effects of CRH on kisspeptin neurons 564 
may exist (Raftogianni et al. 2018; McCosh, Breen, and Kauffman 2019).  565 
 566 
Prolactin: Prolactin is released in response to stress in humans and animals (Levin, Jiang, and Kagan 2018; 567 
Armario et al. 1996; Schedlowski et al. 1992; Theorell 1992; Sonino et al. 2004; Sobrinho 2003). Animal 568 
studies show that prolactin acts through kisspeptin neurons to suppress pulsatile GnRH secretion and 569 
infertility due to hyperprolactinemia can be reversed to some extent by treatment with kisspeptin (Sonigo 570 
et al. 2012). Prolactin also raises secretion of ACTH and augments the adrenal cortex's sensitivity to ACTH, 571 
thus resulting in high corticosterone release even with low levels of ACTH (Weber and Calogero 1991).  572 
 573 
Adrenergic pathways  574 
Acute stress results in the elevated secretion of catecholamines from the adrenal medulla and the 575 
activation of brainstem adrenergic neurons (William Tank and Lee Wong 2014). The effects of adrenaline 576 
and noradrenaline on LH secretion have been known for many decades (Sawyer 1975) but the precise 577 
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mechanisms through which they modulate GnRH secretion remain unclear (Herbison 2015). In general, 578 
adrenergic inputs to the GnRH neuronal network are thought to exert a permissive role in enabling the 579 
network to function optimally for both pulsatile and surge secretion (Herbison 1997; Anselmo-Franci et 580 
al. 1997; Gallo et al. 1989, Scott and Clarke, 1993; Goodman et al., 1995). Nevertheless, in 581 
gonadectomised animals, noradrenaline consistently suppresses pulsatile LH secretion (Herbison 1997). 582 
Electrophysiological studies in mice have revealed that the activation of adrenergic receptors on GnRH 583 
neurons was exclusively inhibitory (Han and Herbison 2008). Thus, it seems likely that the brainstem 584 
adrenergic neurons innervate multiple components of the GnRH neuronal network where they may exert 585 
different effects depending upon their level of activation (Herbison 1997). For example, under states of 586 
heightened activation, they may provide a predominant direct inhibition of GnRH neurons to aid in the 587 
suppression of pulsatile LH secretion. 588 
  589 
 The likelihood of occurrence of FHA and return of menses may be influenced by an individual’s sensitivity 590 
to stress. Evidence in humans and monkeys indicates that alterations in brain serotonin transmission play 591 
a role in determining am individuals sensitivity to stress (Bethea, Centeno, and Cameron 2008; Tancer et 592 
al., 1994; Ressler and Nemeroff, 2000; Bhagwagar et al., 2002). Stress-sensitive monkeys were found to 593 
have diminished serotonergic activity and administration of a serotonin reuptake inhibitor (citalopram) 594 
improves stress resilience (Lima et al. 2009; Bethea et al. 2005). Human and animal studies have also 595 
indicated that a serotonin transporter gene variant is involved in individual stress susceptibility and 596 
related suppression of LH secretion (Caspi et al. 2010; Caspi et al. 2003; Grabe et al. 2005; Michopoulos 597 
et al. 2009). Notably, a decrease in ovarian steroid hormone concentrations was found to suppress 598 
serotonin neural function in monkeys (Bethea et al. 2002; Bethea et al. 2005) but it remains unclear to 599 
what extent circulating steroid levels are involved in maintaining FHA in women. Women with greater 600 
stress resilience show a reduced risk for irregular menstrual cycles when experiencing low to moderate 601 
chronic stress (Palm-Fischbacher and Ehlert 2014).  However, no studies evaluating stress-resilience in the 602 




Lifestyle factors 605 
Cigarette smoking is associated with higher rates of menstrual disorders (Buck et al. 1997; Howe et al. 606 
1985). Several biologic mechanisms have been proposed to underlie this, such as actions on the 607 
hypothalamic-pituitary-ovarian axis, a direct toxic effect on the ovary, and alterations in peripheral 608 
estrogen production (Weisberg 1985). In a study of 2544 college students, cigarette smoking showed a 609 
dose-dependent relationship with the risk for FHA (Johnson and Whitaker 1992). Smoking more than one 610 
packet of cigarettes per day was associated with a 1.96 increased relative risk for persisting amenorrhea. 611 
Unfortunately, no information was available on the lifetime duration of smoking. The well-established 612 
association between smoking and lower BMI (Rasky, Stronegger, and Freidl 1996) is a potential confound 613 
but student smokers in that study had the same relative weight as non-smokers.  614 
The effect of alcohol intake on the menstrual cycle has not been clearly established (Grodstein, Goldman, 615 
and Cramer 1994; Mello 1988). Recent moderate alcohol intake does not appear to have adverse short-616 
term effects on menstrual cycle function (Schliep et al. 2015; Shilaih et al. 2017). The only study 617 
investigating alcohol intake in the context of prolonged amenorrhea showed no association between 618 
alcohol consumption and persistence of FHA (Johnson and Whitaker 1992). These findings have to be 619 
interpreted with caution as alcohol intake was self-reported.  620 
 621 
Genetic factors 622 
Genetic factors influence age at menarche (Dvornyk and Waqar ul 2012) and at menopause (Voorhuis et 623 
al. 2010) and will very likely also be involved in the regulation of the menstrual cycle. Rare gene variants 624 
associated with idiopathic hypogonadotropic hypogonadism in women with hypothalamic amenorrhea, 625 
may influence susceptibility to functional changes in GnRH secretion (Caronia et al. 2011). Also, in 626 
comparison to regularly menstruating runners, runners with FHA reported more eating disorders or major 627 




Treatment options trailed for re-onset and maintenance of menstruation 630 
Medical treatment options for facilitating the recovery of menses include gonadal hormonal therapy 631 
(Falsetti et al. 2002; Genazzani et al. 2012; Shen, Xu, and Lin 2013), recombinant human leptin 632 
(metreleptin) (Chou et al. 2011; Welt et al. 2004) or opioid receptor blockers (naltrexone) (Genazzani et 633 
al. 1995). Altogether, six prospective studies are available (3 of low, 1 of middle and 2 of high quality). 634 
 635 
Medication 636 
Estrogen: The association between estrogens and female weight has been previously reported (Leeners 637 
et al. 2017). An increase in estradiol levels resulting from follicular maturation and conversion of 638 
androgens to estrogens in fat tissue (associated with weight gain) is confirmed in all of the studies 639 
investigating hormonal levels in resumption of menses (Arimura et al. 2010; Audi et al. 1998; Barakat et 640 
al. 2016; Cominato et al. 2014; Holtkamp et al. 2003; Jacoangeli et al. 2006; Karountzos et al. 2017; Pitts 641 
et al. 2014; Tokatly Latzer et al. 2019). Estrogen increases GnRH receptor gene expression and enhances 642 
the ability of FSH to induce expression of LH receptors and promote follicular growth (Turzillo, Nolan, and 643 
Nett 1998; Richards et al. 1976). This has generated the hypothesis that the pituitary response to GnRH 644 
and the ovarian response to gonadotropin could be reinforced with estrogen. However, studies evaluating 645 
this hypothesis failed to show any effect on the likelihood of recovery of menses (Falsetti et al. 2002; 646 
Genazzani et al. 2012; Shen, Xu, and Lin 2013).  647 
 648 
Metreleptin: Recombinant human leptin (metreleptin) facilitated the recovery of menses in women with 649 
FHA due to low body weight, excessive exercise or unspecified reasons (Chou et al. 2011; Welt et al. 2004). 650 
With two daily subcutaneous doses (0.08-0.12 mg/kg body weight) to mimic normal diurnal patterns, 651 
recovery of menses occurred after 28 days up to 32 weeks (Welt et al. 2004; Chou et al. 2011; Wong et 652 
al. 2004). In women, without return of menses during the study period, continuous improvement of 653 
follicular maturation was confirmed by ultrasound and laboratory parameters (Welt et al. 2004). 654 
Important adverse effects of metreleptin application include a decrease in appetite that is counter-655 
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productive to energy status (Welt et al. 2004; Chou et al. 2011). Although results are promising, further 656 
investigations are necessary to determine the efficacy and safety of metreleptin treatment including dose-657 
finding and treatment duration studies in different background characteristics.  658 
 659 
Naltrexone: The long-acting opioid receptor blocker naloxone increases LH pulse frequency and amplitude 660 
in amenorrheic women (Quigley et al. 1980; Khoury et al. 1987) and, as such, naltrexone has been tested 661 
to induce the recovery of menses. Administration of 50-150 mg/d was found to have no effect (Remorgida 662 
et al. 1990), a moderate effect (Armeanu, Berkhout, and Schoemaker 1992), or full return of menses 663 
(Wildt and Leyendecker 1987; Wildt et al. 1993). In the most recent placebo-controlled study, 24 (80%) 664 
women with FHA due to weight loss reported menstrual bleeding within 90 days after initiation of 665 
naltrexone therapy (Genazzani et al. 1995). After three months of treatment, LH plasma levels and pulse 666 
amplitude increased whereas FSH plasma levels did not show any change. The recovery of menstrual 667 
cycles occurred prior to weight gain, suggesting that naltrexone had a central effect independent from 668 
body weight gain. Six months after naltrexone discontinuation, 75% of the women were still 669 
eumenorrheic. Although only minor side effects such as nausea at the beginning of treatment have been 670 
reported, further studies are necessary to determine the efficacy and safety in a larger sample of women 671 
with FHA distinguished by its trigger.  672 
 673 
Psychotherapeutic interventions 674 
Women with FHA, especially those with eating disorders, often experience fear of weight gain, concerns 675 
about dieting, weight judgements of others, perfectionistic performance standards, tendencies to engage 676 
in binge eating, excessive exercise, or depressive symptoms (Fries, Nillius, and Pettersson 1974; Faust et 677 
al. 2013; Brambilla et al. 2003; Favaro and Santonastaso 2009; Giles and Berga 1993; Marcus, Loucks, and 678 
Berga 2001). Many of these characteristics can effectively be treated by CBT (Berga and Loucks 2006; 679 
Berga et al. 2003; Michopoulos et al. 2013). CBT may successfully modify eating and exercise patterns, 680 
maladaptive attitudes concerning body image and weight regulation as well as problem-solving 681 
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techniques (Marcus, Loucks, and Berga 2001; Giles and Berga 1993; Mountjoy et al. 2018; Pauli and Berga 682 
2010). CBT has been shown to promote the return of menses alongside the recovery of cortisol or leptin 683 
levels (Berga, Daniels, and Giles 1997; Berga et al. 2003; Michopoulos et al. 2013; Berga and Loucks 2006). 684 
Besides CBT, hypnotherapy may be helpful in women with FHA (Tschugguel and Berga 2003). Coping skills 685 
such as relaxation, distress tolerance, meditation and mindfulness or yoga provided further positive 686 
effects (Katterman et al. 2014; Rani et al. 2011; Goyal et al. 2014; Hall et al. 2016; Berkman et al. 2006), 687 
but have not directly been investigated in their effect on recovery of menses.   688 
 689 
Discussion  690 
While disturbances of the menstrual cycle in association with weight loss and reduced energy balance are 691 
relatively well understood, knowledge on which conditions and whether menses recovers after FHA is 692 
rather limited. Recently published guidelines of the Endocrine Society provide well-founded recommend-693 
dations for the diagnosis of FHA as well as the treatment of its consequences such as bone loss, infertility 694 
or eventual cardiovascular impairment (Gordon et al. 2017). The present review focusses on the return 695 
of menses, i.e. expand these guidelines into the physiology of recurrence of the menstrual cycle and 696 
options to end FHA.  697 
 698 
Providing a comprehensive account of the return of menses after FHA is challenged by the many 699 
methodological differences used in study designs examining this issue and the difficulties in teasing out 700 
the impact of the influencing factors. Research groups use various definitions of FHA and also of the return 701 
of menses; for example, with regard to the total number of cycles requested, the regularity of cycles, or 702 
the presence of ovulation. Only 11 of the 31 studies exploring recovery of menses after FHA presented a 703 
definition of the return of menses and often the duration of initial amenorrhea is not reported. Most 704 
studies do not differentiate between full ovulatory cycles and partial recovery.  705 
In addition, the conditions to be met to initiate the observation phase [i.e. body weight/BMI, energy 706 
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intake/expenditure, etc.] when return of menses can justifiably be expected, are often either not defined, 707 
not confirmed, or not controlled for stability during the observation phase. A further important point is 708 
the marked variation in the total length of the follow-up period.  709 
We also note that many different approaches have been used to define and evaluate influencing factors 710 
such as measures of weight/body fat, energy balance, nutrition, psychological and lifestyle factors. Often, 711 
studies have not controlled for well-known hormonal causes of cycle disturbances and endocrine 712 
diseases. This is particularly important as, at present, we cannot distinguish between causes and 713 
consequences for most gut hormones, or other laboratory parameters. Differences in study groups 714 
related to causes of FHA, age, ethnicity, psychological background conditions and small sample sizes 715 
further challenge the generalizability of findings.  716 
Only twelve studies had a prospective design and currently no prospective longitudinal studies exist with 717 
adequately powered study groups that control for relevant confounders to allow a reliable estimation of 718 
the frequency and timing of recovery of menses. Consequently, our knowledge of the prevalence of 719 
recovery of menses come from studies that are of a very limited quality. Today, we cannot identify women 720 
with an increased risk for long-term FHA even after weight/BMI and energy availability have been 721 
normalized. It is very likely that psychological factors and stress are involved in those women returning to 722 
normal weight without a return of menses (Gordon et al. 2017), but presently no studies on success rates 723 
of treatment concepts including both organic and psychological factors are available. Therefore, we can 724 
not as yet answer the question if the return of menses can be reliably achieved with adequate treatment. 725 
 726 
While there is abundant research on the onset of the cycle during puberty and the initiation of 727 
amenorrhea in the case of weight loss or unfavourable energy balance, literature on the physiology of 728 
recovery of menses is virtually non-existent. Animal studies have allowed understanding of the regulation 729 
of the pulse generator and how different gut hormones interact with the GnRH neuronal network, but 730 
more research is needed, to better understand the regulatory mechanisms involved in the recovery of 731 
menses in women.  732 
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Although study designs vary considerably with regard to parameters and techniques chosen, research 733 
findings consistently support the importance of maintaining of a stable normal weight, a minimum 734 
amount of body fat and adequate energy availability for recovery of menses. However, we lack a reliable 735 
basis to suggest target weights or energy balance that would allow the recovery of menses in individual 736 
women. Also, we cannot predict if the menstrual cycle recovers after the normalization of weight and 737 
energy balance in individual women and how lifestyle or psychological factors are involved. Studies 738 
examining the association between sport and return of menses show higher chances of recovery in normal 739 
weight women when energy availability increases in most but not in all studies. The small number of study 740 
participants, self-reported food intake (known to be biased by underreporting) and limited precision of 741 
the evaluation of energy balance might explain differences in findings.  742 
The calculation of nutritional needs based on total energy expenditure and sufficient carbohydrate and 743 
protein requirements derived from individual goals and sport-specific regimens is the major factor 744 
promoting the return of menses in athletes (Arends et al. 2012; Cialdella-Kam et al. 2014; Kopp-Woodroffe 745 
et al. 1999; Lagowska et al. 2014; Mallinson et al. 2013; Reed et al. 2015). In contrast, weight recovery is 746 
the most important factor in women with FHA due to eating disorders (Dempfle et al. 2013; Golden et al. 747 
1997; Golden et al. 2008; Faust et al. 2013). While an indirect effect of psychological factors especially in 748 
the context of eating disorders is well established, the direct effect of previous and current psychological 749 
factors warrants further exploration. Very likely, subtle persisting characteristics of eating behaviours, 750 
exercise and energy balance are involved in augmenting the risk for prolonged amenorrhea but remain to 751 
be elucidated.  752 
Overall, the time to return of menses seems to depend on the initial cause of FHA with shorter 753 
duration till recovery in athletes (Cialdella-Kam et al. 2014) compared to women with eating disorders 754 
(Karountzos et al. 2017). The inhomogeneity of studies and the lack of systemic consideration of 755 
influencing factors hampers development of good and robust prediction models.       756 
                                                                                                                                     757 
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Comparative studies or reviews on the effect of different treatment strategies to improve chances for 758 
return of menses do not exist. Interventions such as increase in weight/ energy availability or adaptation 759 
of nutrition have been confirmed to facilitate the return of menstruation, however, specific nutrition 760 
concepts have only been investigated in athletes. Stress management is part of the therapeutic approach 761 
with eating disorders, but its role to improve chances for return of menses has not been fully explored 762 
yet.  In addition to the well-known strategies of adequate weight/BMI/percentage body fat, energy 763 
balance and psychological well-being, drugs as metreleptin or naltrexone have showed favourable results 764 
in some studies but need further investigation. 765 
 766 
Open research questions 767 
More methodologically well-designed studies are needed to close the present gap in our understanding 768 
on how the return of menses in FHA can be facilitated. This includes clear definitions and diagnostic 769 
criteria of FHA, return of menses, conditions at the beginning of an observation period, interventions and 770 
influencing factors/ potential confounders. Further research should address clinically relevant therapeutic 771 
targets values for weight, BMI and energy levels as well as overall chances for return of menses. Studies 772 
should be prospective, longitudinal and include control groups with medications and other therapeutic 773 
interventions tested in a placebo-controlled double-blind design, wherever possible. The pathophysiology 774 
of return of menses should also be evaluated in human studies, cover central and peripheral regulatory 775 
mechanisms, actual psychological stressors, early stress experiences, as well as genetic and epigenetic 776 
factors involved in biological and psychological influences. The latter could serve to identify women at risk 777 
for FHA and enable preventive measures. 778 
 779 
Practical advice 780 
Clinicians should inform women with FHA on the potential long-term consequences of amenorrhea and 781 
the likelihood for return of menses under adequate as well as inadequate conditions. Extensive 782 
counselling may be needed in the case of psychopathology or in high performance athletes. As FHA is 783 
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often the combined effect of low weight, excessive exercise, poor nutrition and psychological factors, 784 
evaluation of the cause of amenorrhea should always include the exploration of all relevant factors and 785 
be carefully differentiated from organic causes of amenorrhea. FHA can persist for several years even 786 
after achieving healthy weight/ adequate energy balance and has severe long-term effects if not treated. 787 
A such, it is important to aim as early as possible for normal cycle function. Therapeutic support should 788 
include adequate nutrition, energy balance, exercise level and mental health. Ideally, support should be 789 
provided by an interdisciplinary team of a gynaecologist-obstetrician, a dietitian and a mental health 790 
professional. In particular, behavioural changes needed for the improvement of energy balance may 791 
necessitate psychotherapeutic support. Non-drug treatment options that eliminate the causes of FHA 792 
remain the therapy of choice to regain menstruation. Predicting if and when menses will return is difficult. 793 
As the chances for pregnancy strongly rely on women’s age (Leeners et al. 2013; Somigliana et al. 2016), 794 
medically-assisted reproduction support should be discussed when menses do not reoccur despite 795 
adequate nutrition, weight, energy balance and stress management.  796 
 797 
Conclusion 798 
Based on the limited evidence available, the restoration of adequate weight/BMI and energy balance have 799 
a clear beneficial effect, but normalization of these factors alone does not reliably result in return of 800 
menses. As the physiology of the return of menses and the underlying factors are only poorly understood, 801 
it seems unlikely that a precise prediction model for when the menstrual cycle will recover in individual 802 
women will be achieved in the near future. Given the severe impact of FHA on womens’ overall and 803 
reproductive health, there is a clear and urgent need for further research investigating the factors 804 
allowing return of menses. Currently, a combination of adequate nutrition, weight, energy balance and 805 
stress management still seems to be the most adequate approach to increase chances for the recovery of 806 
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